| Identification | More | [Name]
N,N-Dimethylglycine hydrochloride | [CAS]
2491-06-7 | [Synonyms]
DIMETHYLAMINOACETIC ACID HYDROCHLORIDE
DIMETHYLGLYCINE HCL
DIMETHYL GLYCINE HYDROCHLORIDE
DMG HYDROCHLORIDE
H-GLY(2ME)-OH HCL
IFLAB-BB F1929-1772
N,N-DIMETHYLAMINOACETIC ACID HYDROCHLORIDE
N,N-DIMETHYLGLYCINE HCL
N,N-DIMETHYLGLYCINE HYDROCHLORIDE
N,N-DIMETHYL-GLY-OH HCL
n,n-dimethyl-glycinhydrochloride
n-methylsarcosinehydrochloride
N,N-dimethylglycinium chloride
Glycine, N,N-dimethyl-, hydrochloride
N,N-DIMETHYLGLYCINE HYDROCHLORIDE 99%
2-(DIMETHYLAMINO)ACETIC ACID HYDROCHLORIDE
N,N,Dimethyl Glycine HCL (DMG) | [EINECS(EC#)]
219-648-2 | [Molecular Formula]
C4H10ClNO2 | [MDL Number]
MFCD00012610 | [Molecular Weight]
139.58 | [MOL File]
2491-06-7.mol |
| Chemical Properties | Back Directory | [Appearance]
white crystalline powder | [Melting point ]
189-194 °C(lit.)
| [Boiling point ]
397.74℃[at 101 325 Pa] | [density ]
1.326[at 20℃] | [vapor pressure ]
0Pa at 25℃ | [storage temp. ]
Store below +30°C. | [solubility ]
DMSO: 10 mg/ml; PBS (pH 7.2): 10 mg/ml | [form ]
Crystalline Powder | [color ]
White | [Odor]
Slight to none | [Water Solubility ]
100 g/L (20 ºC) | [Sensitive ]
Hygroscopic | [Merck ]
14,3244 | [BRN ]
3910578 | [InChI]
1S/C4H9NO2.ClH/c1-5(2)3-4(6)7;/h3H2,1-2H3,(H,6,7);1H | [InChIKey]
FKASAVXZZLJTNX-UHFFFAOYSA-N | [SMILES]
[Cl-].N(CC(=O)O)(C)C.[H+] | [LogP]
-0.3 | [CAS DataBase Reference]
2491-06-7(CAS DataBase Reference) | [EPA Substance Registry System]
2491-06-7(EPA Substance) |
| Safety Data | Back Directory | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
2
| [RTECS ]
MB9995000
| [TSCA ]
Yes | [HS Code ]
29212900 | [Storage Class]
11 - Combustible Solids |
| Hazard Information | Back Directory | [Chemical Properties]
white crystalline powder | [Uses]
N,N-Dimethylglycine (DMG) is a natural N-methylated glycine that is used in comparative analysis with other N-methylated glycines such as sarcosine and βine. Used in the development of glycine-based ionic liquids and emulsifiers. Also it is potentially useful as a biomarker of protein degradation in COPD patients. DMG is used as a substrate to identify, differentiate and characterize amino acid methyltransferase(s). | [Flammability and Explosibility]
Notclassified | [Biochem/physiol Actions]
N,N-Dimethylglycine (DMG) is a natural N-methylated glycine that is used in comparative analysis with other N-methylated glycines such as sarcosine and βine. N,N-Dimethylglycine is used in the development of glycine-based ionic liquids and emulsifiers. N,N-Dimethylglycine is potentially useful as a biomarker of protein degradation in COPD patients. DMG is used as a substrate to identify, differentiate and characterize amino acid methyltransferase(s). | [in vivo]
N,N-Dimethylglycine (30-100 mg/kg; intraperitoneal injection; twice a day; 14 days) hydrochloride prevents the behavioral abnormalities and synaptic dysfunction induced by repeated drug exposure in male ICR mice[1].
N,N-Dimethylglycine (12 mg/0.3 mL sterile saline; gavage; single dose; subcutaneous injection 1 hour later) hydrochloride improves the histological morphology of the small intestine, enhances the antioxidant system, reduces oxidative damage, and increases the expression of antioxidant-related genes in male Kunming mice[2].
N,N-Dimethylglycine (12 mg/0.3 mL sterile saline; gavage; twice a day; 28 days) hydrochloride increases the body weight, the organ proportion of the liver and spleen, enhances the antioxidant capacity of serum and liver, and reduces the activities of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as well as the malondialdehyde (MDA) content in serum and liver in male Kunming mice[3].
N,N-Dimethylglycine (12 mg/0.3 mL sterile saline; gavage; twice a day; 28 days) hydrochloride reduces the serum ALT and AST contents, the ROS level in hepatic mitochondria, and increases the antioxidant capacity of hepatic mitochondria and the mitochondrial membrane potential (MMP) level in male Kunming mice with Lipopolysaccharides (LPS) (HY-D1056)-induced oxidative stress model[3].
| Animal Model: | Male ICR mice (body weight 10-12 g, 3-week- old) + Repeated drug exposure (20 mg/kg, i.p., twice daily for 14 days)[1]. | | Dosage: | 30 mg/kg, 100 mg/kg | | Administration: | Intraperitoneal injection, 20 min prior to each drug injection, twice a day, 14 days. | | Result: | Prevented the drug-induced memory impairments in novel location recognition test (NLRT) and novel object recognition test (NORT), social withdrawal in reciprocal social interaction test, and enhanced head twitch response induced by serotonergic hallucinogen. |
| Animal Model: | Male Kunming mice (weight 20-25 g, 40 days old) + Indomethacin injection (10 mg/kg BW)[2]. | | Dosage: | 12 mg/0.3 mL sterile saline | | Administration: | Orally gavage; single dose; and then subcutaneous injection 1 hour later. | | Result: | Improved the histological morphology of the small intestine.
Enhanced the antioxidant system, reduced oxidative damage, and increased the expression of antioxidant-related genes in the small intestine and its mitochondria compared with the indomethacin-treated group2. |
| Animal Model: | Male Kunming mice (weight 20-25 g, 40 days old) + Lipopolysaccharides (LPS) injection (100 μg/kg body weight)[3]. | | Dosage: | 12 mg/0.3 mL sterile saline | | Administration: | Orally gavage; twice a day; 28 days. | | Result: | Significantly decreased the serum ALT and AST content, ROS level, and expression of liver antioxidant gene MnSOD, Gpx1, Sirt1.
Significantly increased the hepatic mitochondrial antioxidant capacity (MnSOD, GSH, GPx, GR) and MMP level compared with the LPS-treated group. |
| [IC 50]
Human Endogenous Metabolite |
|
|